Sanofi-Aventis SA has accepted that it will have to increase the cash component of is bid for Genzyme Corp., and may raise the cash offer to $70 or $71 a share from $69, French daily Le Figaro reported, without citing anyone.
Sanofi is hoping to reach an agreement at an overall price of around $76 a share, including guaranteed value certificates which depend on future performance, the newspaper said.
To contact the editor responsible for this story: David Whitehouse at dwhitehouse1@bloomberg.net
via bloomberg.com
No comments:
Post a Comment